NICE TA704 - Trastuzumab deruxtecan for treating
HER2-positive unresectable or metastatic breast cancer after 2 or more
anti-HER2 therapies
NICE TA862 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (Decision date - March 2023)
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
